Biohaven Ltd. (NYSE:BHVN) Stock Has Consensus Price Target of $18.69 According to Analysts

Key Points

• Biohaven has a “Moderate Buy” consensus rating from 17 analysts, with eight buys, two strong buys, five holds and two sells. The average 12-month price target is $18.69, versus a recent share price of $11.93.
• Institutional investors and hedge funds own 88.78% of the company, with several firms initiating or increasing positions during the second quarter.
• Biohaven reported quarterly EPS of -$0.91, missing the consensus estimate of -$0.76; analysts expect a full-year loss of approximately $3.33 per share.

Shares of Biohaven Ltd. (NYSE:BHVN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seventeen ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, five have given a hold recommendation, eight have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $18.69.

A number of equities research analysts have issued reports on the stock. Morgan Stanley increased their target price on shares of Biohaven from $18.00 to $19.00 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. Citigroup restated a "buy" rating on shares of Biohaven in a research note on Friday, September 18th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Biohaven in a research report on Friday, August 28th. Needham & Company LLC set a $11.00 price objective on Biohaven in a research note on Monday, June 29th. Finally, Bank of America reiterated an "underperform" rating and issued a $11.00 price objective (down from $12.00) on shares of Biohaven in a research note on Monday, June 29th.

Institutional Investors Weigh In On Biohaven

Hedge funds have recently bought and sold shares of the stock. Opaleye Management Inc. purchased a new position in shares of Biohaven in the 2nd quarter valued at about $1,159,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Biohaven during the second quarter worth approximately $60,000. Engineers Gate Manager LP acquired a new stake in Biohaven in the second quarter valued at approximately $581,000. Integrated Wealth Concepts LLC raised its holdings in Biohaven by 10.4% in the second quarter. Integrated Wealth Concepts LLC now owns 12,653 shares of the company's stock valued at $188,000 after acquiring an additional 1,189 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in Biohaven by 1,525.3% in the second quarter. NewEdge Advisors LLC now owns 16,659 shares of the company's stock worth $248,000 after acquiring an additional 15,634 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company's stock.

Biohaven Stock Performance

NYSE BHVN opened at $11.93 on Thursday. The company has a market cap of $1.80 billion, a P/E ratio of -2.57 and a beta of 1.35. The company has a debt-to-equity ratio of 21.23, a current ratio of 4.73 and a quick ratio of 4.73. The stock has a 50-day moving average of $14.03 and a two-hundred day moving average of $12.46. Biohaven has a 1-year low of $7.48 and a 1-year high of $18.57.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.15). As a group, analysts anticipate that Biohaven will post -3.33 EPS for the current year.

Biohaven Company Profile

Biohaven Ltd. NYSE: BHVN is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and immunological disorders. The company uses proprietary drug-development platforms to pursue treatments for conditions with significant unmet medical needs, including migraine, epilepsy, obsessive-compulsive disorder and other central nervous system diseases.

Biohaven's pipeline has included small-molecule and biologic candidates such as troriluzole, an investigational therapy being studied in several neurological disorders, and other programs targeting ion channels, glutamate signaling and immune pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.